Cancer risk from orthopedic prostheses.
Permanent replacement of joints damaged by fracture or arthritis has become common over the last 50 years. Vigilance over possible long-term adverse effects of metal prostheses is required. Some of the metal components are potentially carcinogenic. Prolonged contact of metal alloys with body fluids results in gradual corrosion of even the most inert metals. Three cohost studies of persons with a hip prosthesis have been reported; they provide direct, quantitative observations of cancer risk in a human population with hip prosthesis. The design and the results of these studies are similar. Combining the results sharpens the precision of risk estimates. Collectively, the studies examined cancer risk in 40,945 patients followed up for a mean 8.5 years after hip replacement. Overall, the relative risk of cancer was 1.02 (95 percent CI 1.00 to 1.05). There was an 8 percent excess of haemopoietic malignancy (leukaemia and lymphoma), with a total of 347 cases observed (RR 1.08, 95 percent CI 0.97 to 1.20). Significant deficits of cancers of the breast and large bowel were seen in the two smaller studies, but combined results from all three studies suggest the relative risk is close to unity. Cancer risk in the first 10 years after hip replacement was not different from that expected, but there was an excess of borderline statistical significance 10 or more years after surgery, with a relative risk of 1.08 (95 percent CI 1.00 to 1.13) based on 1,005 cases. All three studies were well-designed and executed. Their results are not alarming, but give no cause for complacency, since the number of patients with a prosthesis and the length of time they live with the prosthesis will increase. A register of malignancy complicating joint prosthesis would not help quantify any risk. Instead, a large cohort study of patients with joint prostheses is needed, including information on the type and composition of the prosthesis and on potential confounding exposures for each patient. Measures of corrosion in cancer cases and of tissue levels of relevant metal ions in cases and controls (prosthesis but no cancer) matched for age, sex, and time since insertion would be valuable. Such a study could be done internationally, using orthopedic units with good clinical records for 10 to 15 years in areas with long-term cancer registration.
Coleman
M P
MP
Epidemiology and Vital Statistics, London School of Hygiene and Tropical Medicine, UK.
D015331:Cohort Studies; D005260:Female; D005387:Finland; D006615:Hip / Q000601:surgery; D006622:Hip Prosthesis / Q000009:adverse effects; D006801:Humans; D007595:Joint Prosthesis / Q000009:adverse effects*; D008297:Male; D009369:Neoplasms / Q000139:chemically induced*; D009520:New Zealand; D009983:Orthopedic Equipment / Q000009:adverse effects*; D013548:Sweden; D013997:Time Factors